Search - tctmd.com

Displaying 941 - 960 of 1032

Sort: Relevancy | Date

News Conference News AHA 2012

No Mortality Benefit with Prolonged Dual Antiplatelet Therapy

November 05, 2012

News Industry News

Study Finds Drug-Eluting Stents Exhibit Some Benefits Over Bare-Metal Stents In Patients Over 80, Though Both Demonstrate Clinical Benefit

October 26, 2012

News Conference News TCT 2012

No Excess Bleeding with EES vs. BMS in Octogenarians Despite Prolonged DAPT

October 26, 2012

Presentation TCT 2012

Proposals for New Short-Term DAPT Use Trials After DES

Presenter: Roxana Mehran

October 25, 2012

Presentation TCT 2012

What Evidence Is Necessary to Shorten DAPT After DES?

Presenter: Fausto Feres

October 25, 2012

News Industry News

Study Finds That Prasugrel May Reduce Cardiovascular Events Among Patients Managed Medically After an Angiogram for Acute Coronary Syndrome

October 24, 2012

News Industry News

PROMUS Element™ and PROMUS Element™ Plus Receive CE Mark Approval for Labeling Update to Include Three-Month Dual Anti-Platelet Therapy

October 24, 2012

News Conference News TCT 2012

Positive Long-Term Results from LEADERS, BioFreedom FIM, ISAR-TEST 5

October 24, 2012

News Conference News TCT 2012

Experts Discuss Need for Development of Next-Generation DES, Insights from Pathology

October 24, 2012

News Conference News TCT 2012

DEBATE-SFA Favors Predilatation with Drug-Eluting Balloon Before BMS

October 24, 2012

News Conference News TCT 2012

DES: The Year in Review

October 23, 2012

News Conference News TCT 2012

DAPT Cessation Within 1 Year Increased Risk for Major Adverse Events

October 23, 2012

Presentation TCT 2012

Rationale and Data for Different DAPT Durations: From 3 to 30 Months (or Longer)

Presenter: David Kandzari

October 22, 2012

Presentation TCT 2012

PARIS 1-Year: Impact of DAPT Cessation and Non-adherence on Adverse Events Following PCI

Presenter: Roxana Mehran

October 22, 2012

Presentation TCT 2012

DAPT Trial Update

Presenter: Laura Mauri

October 22, 2012

News Conference News TCT 2012

Several Trials Highlight DES Comparisons

October 22, 2012

News Industry News

Analysis Of Medtronic Stent Finds Early Cessation Of Dual Antiplatelet Therapy Caused No Increased Risk Of Blood Clots To One Year

October 22, 2012

News Industry News

Revascularization with OrbusNeich’s Genous™ Stent May Enable the Safe and Early Discontinuation of Dual Antiplatelet Therapy for Patients with Increased Bleeding Risk

October 12, 2012

News Daily News

Studies Suggest Less Stringent Dual Antiplatelet Use After DES

September 20, 2012

News Daily News

Studies Suggest Less Stringent Dual Antiplatelet Use After DES

September 20, 2012

Advertisement

No Mortality Benefit with Prolonged Dual Antiplatelet Therapy

Study Finds Drug-Eluting Stents Exhibit Some Benefits Over Bare-Metal Stents In Patients Over 80, Though Both Demonstrate Clinical Benefit

No Excess Bleeding with EES vs. BMS in Octogenarians Despite Prolonged DAPT

Proposals for New Short-Term DAPT Use Trials After DES

What Evidence Is Necessary to Shorten DAPT After DES?

Study Finds That Prasugrel May Reduce Cardiovascular Events Among Patients Managed Medically After an Angiogram for Acute Coronary Syndrome

PROMUS Element™ and PROMUS Element™ Plus Receive CE Mark Approval for Labeling Update to Include Three-Month Dual Anti-Platelet Therapy

Positive Long-Term Results from LEADERS, BioFreedom FIM, ISAR-TEST 5

Experts Discuss Need for Development of Next-Generation DES, Insights from Pathology

DEBATE-SFA Favors Predilatation with Drug-Eluting Balloon Before BMS

DES: The Year in Review

DAPT Cessation Within 1 Year Increased Risk for Major Adverse Events

Rationale and Data for Different DAPT Durations: From 3 to 30 Months (or Longer)

PARIS 1-Year: Impact of DAPT Cessation and Non-adherence on Adverse Events Following PCI

DAPT Trial Update

Several Trials Highlight DES Comparisons

Analysis Of Medtronic Stent Finds Early Cessation Of Dual Antiplatelet Therapy Caused No Increased Risk Of Blood Clots To One Year

Revascularization with OrbusNeich’s Genous™ Stent May Enable the Safe and Early Discontinuation of Dual Antiplatelet Therapy for Patients with Increased Bleeding Risk

Studies Suggest Less Stringent Dual Antiplatelet Use After DES

Studies Suggest Less Stringent Dual Antiplatelet Use After DES

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content